{"title":"在胆汁淤积压力下,肝脏 FXR-FGF4 需要通过 FGFR4-LRH-1 信号节点实现胆汁酸平衡","authors":"Lintao Song, Yushu Hou, Da Xu, Xijia Dai, Jianya Luo, Yi Liu, Zhuobing Huang, Miaomiao Yang, Jie Chen, Yue Hu, Chuchu Chen, Yuli Tang, Zhiheng Rao, Jianjia Ma, Minghua Zheng, Keqing Shi, Chao Cai, Mingqin Lu, Ruqi Tang, Xiong Ma, Zhifeng Huang","doi":"10.1016/j.cmet.2024.09.008","DOIUrl":null,"url":null,"abstract":"Bile acid (BA) homeostasis is vital for various physiological processes, whereas its disruption underlies cholestasis. The farnesoid X receptor (FXR) is a master regulator of BA homeostasis via the ileal fibroblast growth factor (FGF)15/19 endocrine pathway, responding to postprandial or abnormal transintestinal BA flux. However, the <em>de novo</em> paracrine signal mediator of hepatic FXR, which governs the extent of BA synthesis within the liver in non-postprandial or intrahepatic cholestatic conditions, remains unknown. We identified hepatic <em>Fgf4</em> as a direct FXR target that paracrinally signals to downregulate <em>Cyp7a1</em> and <em>Cyp8b1</em>. The effect of FXR-FGF4 is mediated by an uncharted intracellular FGF receptor 4 (FGFR4)-LRH-1 signaling node. This liver-centric pathway acts as a first-line checkpoint for intrahepatic and transhepatic BA flux upstream of the peripheral FXR-FGF15/19 pathway, which together constitutes an integral hepatoenteric control mechanism that fine-tunes BA homeostasis, counteracting cholestasis and hepatobiliary damage. Our findings shed light on potential therapeutic strategies for cholestatic diseases.","PeriodicalId":9840,"journal":{"name":"Cell metabolism","volume":"1 1","pages":""},"PeriodicalIF":27.7000,"publicationDate":"2024-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Hepatic FXR-FGF4 is required for bile acid homeostasis via an FGFR4-LRH-1 signal node under cholestatic stress\",\"authors\":\"Lintao Song, Yushu Hou, Da Xu, Xijia Dai, Jianya Luo, Yi Liu, Zhuobing Huang, Miaomiao Yang, Jie Chen, Yue Hu, Chuchu Chen, Yuli Tang, Zhiheng Rao, Jianjia Ma, Minghua Zheng, Keqing Shi, Chao Cai, Mingqin Lu, Ruqi Tang, Xiong Ma, Zhifeng Huang\",\"doi\":\"10.1016/j.cmet.2024.09.008\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Bile acid (BA) homeostasis is vital for various physiological processes, whereas its disruption underlies cholestasis. The farnesoid X receptor (FXR) is a master regulator of BA homeostasis via the ileal fibroblast growth factor (FGF)15/19 endocrine pathway, responding to postprandial or abnormal transintestinal BA flux. However, the <em>de novo</em> paracrine signal mediator of hepatic FXR, which governs the extent of BA synthesis within the liver in non-postprandial or intrahepatic cholestatic conditions, remains unknown. We identified hepatic <em>Fgf4</em> as a direct FXR target that paracrinally signals to downregulate <em>Cyp7a1</em> and <em>Cyp8b1</em>. The effect of FXR-FGF4 is mediated by an uncharted intracellular FGF receptor 4 (FGFR4)-LRH-1 signaling node. This liver-centric pathway acts as a first-line checkpoint for intrahepatic and transhepatic BA flux upstream of the peripheral FXR-FGF15/19 pathway, which together constitutes an integral hepatoenteric control mechanism that fine-tunes BA homeostasis, counteracting cholestasis and hepatobiliary damage. Our findings shed light on potential therapeutic strategies for cholestatic diseases.\",\"PeriodicalId\":9840,\"journal\":{\"name\":\"Cell metabolism\",\"volume\":\"1 1\",\"pages\":\"\"},\"PeriodicalIF\":27.7000,\"publicationDate\":\"2024-10-10\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cell metabolism\",\"FirstCategoryId\":\"99\",\"ListUrlMain\":\"https://doi.org/10.1016/j.cmet.2024.09.008\",\"RegionNum\":1,\"RegionCategory\":\"生物学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CELL BIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cell metabolism","FirstCategoryId":"99","ListUrlMain":"https://doi.org/10.1016/j.cmet.2024.09.008","RegionNum":1,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CELL BIOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
胆汁酸(BA)稳态对各种生理过程至关重要,而胆汁酸紊乱则是胆汁淤积症的根源。法尼类固醇 X 受体(FXR)是通过回肠成纤维细胞生长因子(FGF)15/19 内分泌途径调节胆汁酸平衡的主调节器,对餐后或异常的经肠胆汁酸通量做出反应。然而,在非餐后或肝内胆汁淤积的情况下,肝脏 FXR 的从头旁分泌信号介质控制着肝脏内 BA 的合成程度,但这一介质仍然未知。我们发现肝脏 Fgf4 是 FXR 的直接靶点,它通过旁分泌信号下调 Cyp7a1 和 Cyp8b1。FXR-FGF4的作用是由未知的细胞内FGF受体4(FGFR4)-LRH-1信号节点介导的。这条以肝脏为中心的通路是肝内和跨肝 BA 通路的一线检查点,位于外周 FXR-FGF15/19 通路的上游,共同构成了一个完整的肝肠控制机制,可微调 BA 平衡,抵消胆汁淤积和肝胆损伤。我们的发现为胆汁淤积性疾病的潜在治疗策略提供了启示。
Hepatic FXR-FGF4 is required for bile acid homeostasis via an FGFR4-LRH-1 signal node under cholestatic stress
Bile acid (BA) homeostasis is vital for various physiological processes, whereas its disruption underlies cholestasis. The farnesoid X receptor (FXR) is a master regulator of BA homeostasis via the ileal fibroblast growth factor (FGF)15/19 endocrine pathway, responding to postprandial or abnormal transintestinal BA flux. However, the de novo paracrine signal mediator of hepatic FXR, which governs the extent of BA synthesis within the liver in non-postprandial or intrahepatic cholestatic conditions, remains unknown. We identified hepatic Fgf4 as a direct FXR target that paracrinally signals to downregulate Cyp7a1 and Cyp8b1. The effect of FXR-FGF4 is mediated by an uncharted intracellular FGF receptor 4 (FGFR4)-LRH-1 signaling node. This liver-centric pathway acts as a first-line checkpoint for intrahepatic and transhepatic BA flux upstream of the peripheral FXR-FGF15/19 pathway, which together constitutes an integral hepatoenteric control mechanism that fine-tunes BA homeostasis, counteracting cholestasis and hepatobiliary damage. Our findings shed light on potential therapeutic strategies for cholestatic diseases.
期刊介绍:
Cell Metabolism is a top research journal established in 2005 that focuses on publishing original and impactful papers in the field of metabolic research.It covers a wide range of topics including diabetes, obesity, cardiovascular biology, aging and stress responses, circadian biology, and many others.
Cell Metabolism aims to contribute to the advancement of metabolic research by providing a platform for the publication and dissemination of high-quality research and thought-provoking articles.